Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan.


Journal

Cancer biotherapy & radiopharmaceuticals
ISSN: 1557-8852
Titre abrégé: Cancer Biother Radiopharm
Pays: United States
ID NLM: 9605408

Informations de publication

Date de publication:
Apr 2023
Historique:
medline: 10 4 2023
pubmed: 15 11 2022
entrez: 14 11 2022
Statut: ppublish

Résumé

Boron neutron capture therapy (BNCT) has been performed at nuclear research reactors for many years. The development of accelerators for BNCT resulted in a paradigm shift from research to real clinical applications. In Japan, BNCT was approved as a clinical therapy covered by the National Health Insurance in 2020. In this article, the status of BNCT in Japan is briefly introduced.

Identifiants

pubmed: 36374236
doi: 10.1089/cbr.2022.0056
pmc: PMC10122211
doi:

Substances chimiques

Boron Compounds 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-207

Commentaires et corrections

Type : ErratumIn

Références

Cancer. 2005 Nov 15;104(10):2168-73
pubmed: 16220556
Oncotarget. 2017 Oct 6;8(53):91779-91794
pubmed: 29207684
Appl Radiat Isot. 2021 Feb;168:109553
pubmed: 33302249
Radiother Oncol. 2021 Feb;155:182-187
pubmed: 33186684
J Clin Oncol. 2017 Jan 20;35(3):343-351
pubmed: 27918718
Clin Cancer Res. 2015 Aug 15;21(16):3610-8
pubmed: 25910950
J Neurooncol. 2017 Jan;131(1):193-199
pubmed: 27770279
Appl Radiat Isot. 2020 Nov;165:109246
pubmed: 32692654
J Neurooncol. 2018 Mar;137(1):39-47
pubmed: 29404979
Neurooncol Adv. 2021 May 20;3(1):vdab067
pubmed: 34151269
J Neurooncol. 2018 Jul;138(3):627-636
pubmed: 29557060
Neurooncol Pract. 2017 Dec;4(4):201-208
pubmed: 31385993
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Neuro Oncol. 2015 Nov;17(11):1504-13
pubmed: 26130744
Clin Transl Radiat Oncol. 2022 Feb 18;33:128-133
pubmed: 35252597
Appl Radiat Isot. 2020 Feb;156:108961
pubmed: 31683088
Sci Rep. 2021 Apr 13;11(1):8090
pubmed: 33850253
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318

Auteurs

Akira Matsumura (A)

Ibaraki Prefectural University of Health Sciences, Ibaraki, Japan.
Proton Medical Research Center, University of Tsukuba, Ibaraki, Japan.

Tomoyuki Asano (T)

Stella Pharma Co. Ltd., Osaka, Japan.

Katsumi Hirose (K)

Department of Radiation Oncology, Southern Tohoku Hospital, Fukushima, Japan.

Hiroshi Igaki (H)

Division of Boron Neutron Capture Therapy Medical Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan.

Shinji Kawabata (S)

Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Hiroaki Kumada (H)

Proton Medical Research Center, University of Tsukuba, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH